BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline · 11 Nov 2026
Retatrutide Phase 3 Data: What TRIUMPH-4 and TRIUMPH-1-OA Mean for the Triple-Agonist GLP-1 Pipeline
Phase 3 trials of Eli Lilly's investigational triple agonist retatrutide, presented at ACR Convergence 2026 and simultaneously published in the New England Journal of Medicine, show significant reductions in knee osteoarthritis pain alongside substantial weight loss. With a biologics licence application targeted for Q1 2027, the compound represents the most advanced triple-agonist peptide in the obesity and musculoskeletal pipeline.
Read briefing →
Regulatory & Policy
FDA Mandates Class-Wide NAION Warning for All GLP-1 Receptor Agonists: What the Labelling Change Means for Research and Procurement
The FDA has required all GLP-1 receptor agonist manufacturers — including Novo Nordisk and Eli Lilly — to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION) to their product labelling, following a meta-analysis of 126 clinical trials and two years of accumulating real-world evidence. The action extends a signal first identified with semaglutide to the entire class, including orforglipron.
10 Nov 2026
Pharma & GLP-1
argenx Acquires Macrocyclic Peptide Specialist Unnatural Products for Up to $1.15 Billion: What the Deal Signals for Oral Peptide Drug Development
argenx has announced a definitive agreement to acquire Unnatural Products, Inc., a macrocyclic peptide discovery biotech, for $550 million upfront and up to $1.15 billion in total consideration. The deal, announced on 9 November 2026, adds an AI-guided peptide platform to argenx's antibody engineering capabilities and signals growing industry conviction that oral and long-acting peptide medicines represent the next frontier in immunology.
09 Nov 2026
Industry & Community
Shilpa CDMO's $50 Million Expansion: What India's Latest Peptide Manufacturing Investment Means for UK Research Supply Chains
Shilpa CDMO announced a $50 million phased investment in solid-phase peptide synthesis capacity at its Raichur, India campus on 3 November 2026, with its first commercial manufacturing line due to open in December. The move reinforces India's emergence as a significant alternative to European and Chinese sources for peptide APIs, with implications for procurement diversification strategies at UK research organisations.
08 Nov 2026
Research Pipeline
BPC-157: Evidence Base, Regulatory Status, and Procurement Considerations for UK Research Laboratories
BPC-157 is the most prominently discussed of the six peptides covered by the October 2026 HHS enforcement discretion policy, yet two formal systematic reviews published this year conclude that human evidence remains very low quality. This briefing summarises the current clinical and preclinical evidence, US and UK regulatory status, and what procurement teams should verify before sourcing the compound.
07 Nov 2026
Pharma & GLP-1
Eli Lilly and Hims & Hers Formalise GLP-1 Distribution Partnership: What the Zepbound and Foundayo Agreement Means for the Compounding Market
Eli Lilly announced on 6 November 2026 a formal distribution agreement with Hims & Hers Health, granting the telehealth platform direct access to Zepbound (tirzepatide) and Foundayo (orforglipron) at standardised self-pay prices. A central clause commits Hims & Hers to discontinue compounded copies of Lilly's GLP-1 medicines, reshaping access dynamics for both approved and unapproved peptide products.
06 Nov 2026
Pharma & GLP-1
AstraZeneca's $10 Billion Offer for Rhythm Pharmaceuticals: What a Cyclic Peptide Acquisition Signals for the Obesity Drug Race
AstraZeneca has made a reported non-binding offer of approximately $10 billion to acquire Rhythm Pharmaceuticals, the maker of setmelanotide (Imcivree) — an FDA-approved cyclic octapeptide that targets the melanocortin-4 receptor in rare genetic obesity. The proposed deal, which would be executed through AstraZeneca's rare-disease unit Alexion, positions the British pharma group for a commercial foothold in the fast-growing obesity market and underscores how peptide-based mechanisms are…
05 Nov 2026
Reputational Risks
Australia's First Confirmed Peptide Fatality: What the CJC-1295 and Ipamorelin Coroner's Findings Mean for Research Procurement
A Victorian coroner has found that the March 2025 death of Australian actor Richard Norton was triggered by injections of unapproved peptides CJC-1295 and Ipamorelin, recommending the TGA consider reclassifying both substances to restrict their use to clinical trials. The case — believed to be Australia's first confirmed peptide fatality — has heightened regulatory scrutiny internationally and carries direct implications for research institutions handling growth-hormone-releasing peptides.
04 Nov 2026
Research Pipeline
Thymosin Alpha-1: Mechanism, Clinical Evidence, and Regulatory Status for UK Research Procurement
Thymosin alpha-1 (Tα1) is a 28-amino-acid immunomodulatory peptide approved as Zadaxin in more than 35 countries — but not by the FDA, MHRA, or EMA. A 2026 scoping review, a 2025 phase 3 sepsis trial, and active vaccine-adjuvant research make it one of the better-evidenced non-approved peptides in circulation. This briefing maps the mechanism, evidence base, regulatory standing, and procurement considerations for UK laboratories.
03 Nov 2026
Regulatory & Policy
First Commercial Pharmacy Secures API Supply for All Six PCAC Peptides: What the Corexa Health Announcement Means for Research Procurement
DataMeds AI's subsidiary Corexa Health announced on 2 November 2026 that it has secured a commercial supply agreement for bulk drug substance and API covering all six PCAC-recommended peptides — BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax — with dispensing planned to begin this month under the HHS enforcement discretion policy. The move signals that the US compounding pharmacy market is beginning to mobilise around the October 28 policy, but formal 503A Bulks List status remains pending…
02 Nov 2026
Research Pipeline
GHK-Cu: Evidence Base, Regulatory Status, and Procurement Considerations for UK Research Laboratories
GHK-Cu, the naturally occurring copper tripeptide, sits at a regulatory inflection point: removed from FDA Category 2 in April 2026, scheduled for a second PCAC review before the end of February 2027, and under active Phase 2 clinical investigation for wound healing. A comprehensive 2026 review in Pharmaceutics confirms robust preclinical signal but sparse clinical evidence — a distinction that matters for procurement and compliance decisions at UK research labs.
01 Nov 2026
Industry & Community
Samsung Biologics Clears the Tender Threshold: What PolyPeptide's Imminent Delisting Means for Peptide API Supply
The additional acceptance period for Samsung Biologics' CHF 1.46 billion bid for Swiss peptide CDMO PolyPeptide Group closed on 30 October, with the main period already confirming an 87.59–87.92% tender rate. Completion is targeted by end of November, pending multi-jurisdiction regulatory clearances. Research procurement teams should now plan for the operational consequences of this ownership change on one of the sector's largest GLP-1 peptide API suppliers.
31 Oct 2026